Literature DB >> 19628698

Repression of alpha-synuclein expression and toxicity by microRNA-7.

Eunsung Junn1, Kang-Woo Lee, Byeong Seon Jeong, Teresa W Chan, Joo-Young Im, M Maral Mouradian.   

Abstract

alpha-Synuclein is a key protein in Parkinson's disease (PD) because it accumulates as fibrillar aggregates in pathologic hallmark features in affected brain regions, most notably in nigral dopaminergic neurons. Intraneuronal levels of this protein appear critical in mediating its toxicity, because multiplication of its gene locus leads to autosomal dominant PD, and transgenic animal models overexpressing human alpha-synuclein manifest impaired function or decreased survival of dopaminergic neurons. Here, we show that microRNA-7 (miR-7), which is expressed mainly in neurons, represses alpha-synuclein protein levels through the 3'-untranslated region (UTR) of alpha-synuclein mRNA. Importantly, miR-7-induced down-regulation of alpha-synuclein protects cells against oxidative stress. Further, in the MPTP-induced neurotoxin model of PD in cultured cells and in mice, miR-7 expression decreases, possibly contributing to increased alpha-synuclein expression. These findings provide a mechanism by which alpha-synuclein levels are regulated in neurons, have implications for the pathogenesis of PD, and suggest miR-7 as a therapeutic target for PD and other alpha-synucleinopathies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19628698      PMCID: PMC2722353          DOI: 10.1073/pnas.0906277106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  47 in total

1.  Sequence variants in SLITRK1 are associated with Tourette's syndrome.

Authors:  Jesse F Abelson; Kenneth Y Kwan; Brian J O'Roak; Danielle Y Baek; Althea A Stillman; Thomas M Morgan; Carol A Mathews; David L Pauls; Mladen-Roko Rasin; Murat Gunel; Nicole R Davis; A Gulhan Ercan-Sencicek; Danielle H Guez; John A Spertus; James F Leckman; Leon S Dure; Roger Kurlan; Harvey S Singer; Donald L Gilbert; Anita Farhi; Angeliki Louvi; Richard P Lifton; Nenad Sestan; Matthew W State
Journal:  Science       Date:  2005-10-14       Impact factor: 47.728

2.  MicroRNA expression in zebrafish embryonic development.

Authors:  Erno Wienholds; Wigard P Kloosterman; Eric Miska; Ezequiel Alvarez-Saavedra; Eugene Berezikov; Ewart de Bruijn; H Robert Horvitz; Sakari Kauppinen; Ronald H A Plasterk
Journal:  Science       Date:  2005-05-26       Impact factor: 47.728

3.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.

Authors:  R Krüger; W Kuhn; T Müller; D Woitalla; M Graeber; S Kösel; H Przuntek; J T Epplen; L Schöls; O Riess
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

4.  Alpha-synuclein in Lewy bodies.

Authors:  M G Spillantini; M L Schmidt; V M Lee; J Q Trojanowski; R Jakes; M Goedert
Journal:  Nature       Date:  1997-08-28       Impact factor: 49.962

5.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

6.  Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

Authors:  Eliezer Masliah; Edward Rockenstein; Anthony Adame; Michael Alford; Leslie Crews; Makoto Hashimoto; Peter Seubert; Michael Lee; Jason Goldstein; Tamie Chilcote; Dora Games; Dale Schenk
Journal:  Neuron       Date:  2005-06-16       Impact factor: 17.173

7.  Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.

Authors:  Eunsung Junn; Ruben D Ronchetti; Martha M Quezado; Soo-Youl Kim; M Maral Mouradian
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-07       Impact factor: 11.205

8.  Alpha-synuclein up-regulation and aggregation during MPP+-induced apoptosis in neuroblastoma cells: intermediacy of transferrin receptor iron and hydrogen peroxide.

Authors:  Shasi V Kalivendi; Sonya Cunningham; Srigiridhar Kotamraju; Joy Joseph; Cecilia J Hillard; B Kalyanaraman
Journal:  J Biol Chem       Date:  2004-01-23       Impact factor: 5.157

9.  Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis.

Authors:  Angie M Cheng; Mike W Byrom; Jeffrey Shelton; Lance P Ford
Journal:  Nucleic Acids Res       Date:  2005-03-01       Impact factor: 16.971

10.  Microarray analysis of microRNA expression in the developing mammalian brain.

Authors:  Eric A Miska; Ezequiel Alvarez-Saavedra; Matthew Townsend; Akira Yoshii; Nenad Sestan; Pasko Rakic; Martha Constantine-Paton; H Robert Horvitz
Journal:  Genome Biol       Date:  2004-08-31       Impact factor: 13.583

View more
  281 in total

Review 1.  Circulating MicroRNA as Potential Source for Neurodegenerative Diseases Biomarkers.

Authors:  Ying Zi; Zhongmin Yin; Weizhong Xiao; Xinwei Liu; Zhixiang Gao; Li Jiao; Lianfu Deng
Journal:  Mol Neurobiol       Date:  2014-11-04       Impact factor: 5.590

2.  Chronic intermittent ethanol exposure and its removal induce a different miRNA expression pattern in primary cortical neuronal cultures.

Authors:  Yingqiu Guo; Yongxin Chen; Stephanie Carreon; Mei Qiang
Journal:  Alcohol Clin Exp Res       Date:  2011-12-05       Impact factor: 3.455

3.  A search for SNCA 3' UTR variants identified SNP rs356165 as a determinant of disease risk and onset age in Parkinson's disease.

Authors:  Lucía F Cardo; Eliecer Coto; Lorena de Mena; René Ribacoba; Oswaldo Lorenzo-Betancor; Pau Pastor; Lluis Samaranch; Ignacio F Mata; Marta Díaz; Germán Moris; Manuel Menéndez; Ana I Corao; Victoria Alvarez
Journal:  J Mol Neurosci       Date:  2011-11-11       Impact factor: 3.444

4.  Next-generation sequencing reveals regional differences of the α-synuclein methylation state independent of Lewy body disease.

Authors:  L de Boni; S Tierling; S Roeber; J Walter; A Giese; Hans A Kretzschmar
Journal:  Neuromolecular Med       Date:  2011-11-01       Impact factor: 3.843

Review 5.  Non-coding RNAs in human disease.

Authors:  Manel Esteller
Journal:  Nat Rev Genet       Date:  2011-11-18       Impact factor: 53.242

Review 6.  Parkinson's disease: gene therapies.

Authors:  Philippe G Coune; Bernard L Schneider; Patrick Aebischer
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

Review 7.  Functions of noncoding RNAs in neural development and neurological diseases.

Authors:  Shan Bian; Tao Sun
Journal:  Mol Neurobiol       Date:  2011-10-04       Impact factor: 5.590

Review 8.  Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed?

Authors:  Sagar Kansara; Akash Trivedi; Sheng Chen; Joseph Jankovic; Weidong Le
Journal:  J Neural Transm (Vienna)       Date:  2012-06-26       Impact factor: 3.575

9.  β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease.

Authors:  Shuchi Mittal; Kjetil Bjørnevik; Doo Soon Im; Adrian Flierl; Xianjun Dong; Joseph J Locascio; Kristine M Abo; Elizabeth Long; Ming Jin; Bing Xu; Yang K Xiang; Jean-Christophe Rochet; Anders Engeland; Patrizia Rizzu; Peter Heutink; Tim Bartels; Dennis J Selkoe; Barbara J Caldarone; Marcie A Glicksman; Vikram Khurana; Birgitt Schüle; David S Park; Trond Riise; Clemens R Scherzer
Journal:  Science       Date:  2017-09-01       Impact factor: 47.728

Review 10.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.